| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RXRX | 41.09% | $2.12B | -29.12% | 0.00% |
| TWST | 37.41% | $2.26B | -21.50% | 0.00% |
| NRIX | 37.15% | $948.37M | -35.91% | 0.00% |
| ARCT | 36.41% | $369.38M | -37.89% | 0.00% |
| CRSP | 36.21% | $4.46B | -4.14% | 0.00% |
| BEAM | 35.98% | $2.00B | -15.33% | 0.00% |
| EDIT | 35.90% | $214.31M | -45.06% | 0.00% |
| PDSB | 35.86% | $58.05M | -57.81% | 0.00% |
| KRYS | 35.84% | $4.08B | -20.39% | 0.00% |
| OCUL | 35.65% | $1.51B | +41.41% | 0.00% |
| AI | 35.55% | $3.47B | -9.59% | 0.00% |
| ARWR | 35.49% | $2.33B | -32.59% | 0.00% |
| KALV | 35.39% | $585.65M | +0.51% | 0.00% |
| DCI | 35.31% | $8.29B | +0.07% | 1.56% |
| COHU | 35.27% | $953.77M | -38.54% | 0.00% |
| VRDN | 34.94% | $1.24B | +24.33% | 0.00% |
| SYRE | 34.77% | $935.48M | -39.83% | 0.00% |
| BC | 34.72% | $3.93B | -14.01% | 2.85% |
| XNCR | 34.66% | $590.72M | -55.40% | 0.00% |
| KAI | 34.55% | $3.88B | +11.40% | 0.39% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -28.21% | $296.22M | 1.43% |
| VIXY | -28.07% | $164.54M | 0.85% |
| TAIL | -23.12% | $99.63M | 0.59% |
| IVOL | -15.02% | $347.03M | 1.02% |
| TPMN | -9.58% | $30.70M | 0.65% |
| ULST | -7.99% | $654.75M | 0.2% |
| FXY | -7.28% | $816.38M | 0.4% |
| UNG | -7.18% | $360.54M | 1.06% |
| FTSD | -6.89% | $231.81M | 0.25% |
| IBTG | -6.05% | $1.92B | 0.07% |
| CORN | -5.79% | $44.67M | 0.2% |
| SPTS | -5.44% | $5.80B | 0.03% |
| STPZ | -4.95% | $450.47M | 0.2% |
| XONE | -4.95% | $625.28M | 0.03% |
| STOT | -4.55% | $254.07M | 0.45% |
| UTWO | -4.06% | $379.52M | 0.15% |
| WEAT | -3.99% | $117.15M | 0.28% |
| VGSH | -3.40% | $22.80B | 0.03% |
| LDUR | -3.18% | $929.65M | 0.5% |
| IBTH | -2.97% | $1.62B | 0.07% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 44.50% | $4.82B | 0.35% |
| ARKG | 44.00% | $1.02B | 0.75% |
| GNOM | 41.02% | $44.57M | 0.5% |
| IBB | 39.86% | $5.26B | 0.45% |
| QCLN | 39.24% | $400.76M | 0.56% |
| PTH | 38.68% | $100.85M | 0.6% |
| IWC | 38.61% | $818.14M | 0.6% |
| PBE | 38.48% | $223.19M | 0.58% |
| ARKK | 37.94% | $6.85B | 0.75% |
| ERTH | 37.82% | $136.20M | 0.67% |
| IWO | 37.62% | $11.60B | 0.24% |
| PBW | 37.33% | $271.53M | 0.65% |
| KOMP | 36.95% | $2.29B | 0.2% |
| FBT | 36.32% | $1.01B | 0.54% |
| PINK | 36.02% | $130.57M | 0.5% |
| ICVT | 36.01% | $2.53B | 0.2% |
| KJUL | 35.65% | $119.50M | 0.79% |
| VTWO | 35.60% | $12.52B | 0.07% |
| IWM | 35.46% | $63.72B | 0.19% |
| SCHA | 35.41% | $17.26B | 0.04% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -12.78% | $24.23B | +35.36% | 1.09% |
| SAND | -10.21% | $2.76B | +67.62% | 0.61% |
| HCA | -9.13% | $90.95B | +15.77% | 0.73% |
| GFI | -8.65% | $21.56B | +57.55% | 2.31% |
| AU | -6.62% | $23.49B | +78.98% | 2.23% |
| DRD | -5.48% | $1.18B | +51.33% | 2.03% |
| EQX | -4.76% | $4.42B | +6.96% | 0.00% |
| EGO | -4.68% | $4.26B | +33.87% | 0.00% |
| HMY | -4.49% | $8.87B | +52.35% | 1.21% |
| KGC | -4.46% | $19.10B | +87.82% | 0.77% |
| T | -4.33% | $203.71B | +51.55% | 3.92% |
| VIV | -4.32% | $18.81B | +44.82% | 0.66% |
| HUSA | -4.26% | $19.66M | -19.53% | 0.00% |
| AGI | -4.11% | $11.34B | +67.62% | 0.37% |
| BTCT | -3.69% | $25.56M | +61.14% | 0.00% |
| CME | -3.58% | $99.39B | +40.68% | 3.86% |
| TK | -3.46% | $630.88M | +10.47% | 0.00% |
| UHS | -3.43% | $11.89B | -0.50% | 0.43% |
| IMMP | -3.30% | $248.27M | -14.14% | 0.00% |
| K | -3.09% | $27.76B | +41.17% | 2.85% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ASPS | 0.03% | $108.30M | -4.13% | 0.00% |
| SKWD | 0.07% | $2.22B | +53.01% | 0.00% |
| CIG | -0.11% | $3.77B | +11.48% | 0.00% |
| TRMD | 0.12% | $1.67B | -56.24% | 23.20% |
| XGN | -0.23% | $152.37M | +285.08% | 0.00% |
| MSEX | 0.27% | $1.00B | +5.97% | 2.41% |
| FDP | 0.27% | $1.59B | +52.62% | 3.31% |
| STNG | 0.28% | $2.14B | -48.70% | 3.80% |
| AEP | 0.30% | $55.16B | +17.93% | 3.54% |
| CPSH | 0.31% | $42.27M | +74.25% | 0.00% |
| HRTG | -0.34% | $702.31M | +250.23% | 0.00% |
| LUMN | 0.36% | $4.57B | +327.88% | 0.00% |
| ARDT | 0.36% | $1.92B | -16.13% | 0.00% |
| CCEC | -0.37% | $1.02B | +3.91% | 2.58% |
| KR | -0.43% | $46.43B | +38.38% | 1.85% |
| FATBB | -0.46% | $49.01M | -5.66% | 10.18% |
| MKTX | 0.46% | $8.22B | +9.03% | 1.38% |
| TEF | -0.48% | $30.08B | +25.41% | 6.16% |
| ZCMD | 0.48% | $29.55M | -8.59% | 0.00% |
| IMNN | 0.49% | $16.26M | -34.16% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SHYM | -0.01% | $357.13M | 0.35% |
| IBD | 0.03% | $385.27M | 0.43% |
| SOYB | 0.10% | $26.67M | 0.22% |
| CMBS | -0.11% | $449.66M | 0.25% |
| OUNZ | -0.14% | $1.73B | 0.25% |
| GDX | 0.33% | $15.49B | 0.51% |
| AAAU | -0.34% | $1.54B | 0.18% |
| SPSK | -0.35% | $321.02M | 0.5% |
| TFLO | -0.37% | $6.82B | 0.15% |
| CTA | 0.39% | $1.06B | 0.76% |
| GLD | -0.40% | $100.19B | 0.4% |
| GOAU | 0.45% | $124.14M | 0.6% |
| USDU | 0.46% | $162.43M | 0.5% |
| SGOL | -0.47% | $5.17B | 0.17% |
| SMB | 0.52% | $274.97M | 0.07% |
| KCCA | 0.52% | $109.43M | 0.87% |
| BAR | -0.62% | $1.11B | 0.1749% |
| IAU | -0.65% | $46.70B | 0.25% |
| BNO | 0.77% | $103.79M | 1% |
| USO | 0.84% | $1.13B | 0.6% |
Double maintains 2 strategies that include IBRX - ImmunityBio, Inc.
Yahoo
ImmunityBio, Inc. (NASDAQ:IBRX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With a price target of $8, H.C. Wainwright analysts reiterated their Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX) on June 4. The decision comes after the company’s recent regulatory triumphs, which include the FDA’s Expanded Access authorization […]
Yahoo
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it attained Expanded Access authorization from the U.S. Food and Drug Administration, FDA, for its Cancer BioShield platform, anchored by ANKTIVA, to treat lymphopenia, a life-threatening immune deficiency induced by […]
Yahoo
Over the last 7 days, the United States market has risen 1.2% and is up 11% over the last 12 months, with earnings forecast to grow by 14% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable market conditions.
SeekingAlpha
ImmunityBioâs Anktiva holds bladder cancer promise despite FDA hurdles, while its lymphopenia treatment could unlock major upside. Learn why IBRX stock is a buy.
Yahoo
We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other Wednesday’s best-performing stocks. ImmunityBio extended its winning streak to a fifth consecutive day on Wednesday, jumping 8.1 percent to finish at $2.93 apiece […]
Finnhub
CULVER CITY - ImmunityBio, Inc. announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy.This data supports that reversal of lymphopenia,...
Current Value
$2.711 Year Return
Current Value
$2.711 Year Return
